Franklin Street Advisors Inc. NC Has $18.84 Million Position in IDEXX Laboratories, Inc. $IDXX

Franklin Street Advisors Inc. NC grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 35,131 shares of the company’s stock after buying an additional 3,222 shares during the quarter. Franklin Street Advisors Inc. NC’s holdings in IDEXX Laboratories were worth $18,842,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in IDXX. Red Spruce Capital LLC increased its position in IDEXX Laboratories by 1.1% during the 2nd quarter. Red Spruce Capital LLC now owns 1,701 shares of the company’s stock worth $912,000 after purchasing an additional 19 shares in the last quarter. Rise Advisors LLC increased its position in IDEXX Laboratories by 3.9% during the 2nd quarter. Rise Advisors LLC now owns 562 shares of the company’s stock worth $301,000 after purchasing an additional 21 shares in the last quarter. Sage Mountain Advisors LLC increased its position in IDEXX Laboratories by 3.8% during the 1st quarter. Sage Mountain Advisors LLC now owns 635 shares of the company’s stock worth $267,000 after purchasing an additional 23 shares in the last quarter. Great Lakes Advisors LLC increased its position in IDEXX Laboratories by 0.9% during the 1st quarter. Great Lakes Advisors LLC now owns 2,567 shares of the company’s stock worth $1,078,000 after purchasing an additional 23 shares in the last quarter. Finally, PDS Planning Inc increased its position in IDEXX Laboratories by 3.9% during the 1st quarter. PDS Planning Inc now owns 641 shares of the company’s stock worth $269,000 after purchasing an additional 24 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IDXX has been the subject of a number of research analyst reports. Leerink Partners upped their price objective on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. UBS Group initiated coverage on shares of IDEXX Laboratories in a research report on Wednesday. They issued a “neutral” rating and a $720.00 price target for the company. BTIG Research upped their price target on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. Stifel Nicolaus set a $640.00 price target on shares of IDEXX Laboratories in a research report on Monday, August 4th. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Sunday, September 28th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $656.50.

Insider Buying and Selling at IDEXX Laboratories

In related news, CEO Jonathan Jay Mazelsky sold 29,260 shares of the stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the transaction, the chief executive officer directly owned 83,311 shares of the company’s stock, valued at $52,650,885.78. This represents a 25.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Nimrata Hunt sold 7,143 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $630.43, for a total transaction of $4,503,161.49. Following the transaction, the executive vice president directly owned 18,007 shares in the company, valued at approximately $11,352,153.01. This represents a 28.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,057 shares of company stock valued at $34,293,468 over the last 90 days. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Down 0.4%

NASDAQ:IDXX opened at $631.19 on Friday. The firm’s fifty day moving average is $634.52 and its 200-day moving average is $534.79. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $688.12. The firm has a market cap of $50.50 billion, a P/E ratio of 52.56, a P/E/G ratio of 4.10 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating analysts’ consensus estimates of $3.28 by $0.35. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company’s quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.